OBJECTIVES:  To assess compliance and discontinuation rates with DMTs in Canadian patients with RRMS. METHODS: In this Canadian retrospective claims analysis based on IMS Rx Dynamics® database, patients had ≥1 prescription filled for each DMT (oral: fingolimod, dimethyl fumarate (DMF), teriflunomide; injectable (BRACE): interferon beta-1a, interferon beta-1b, glatiramer acetate; infusible: natalizumab). Patients were considered compliant if the medication possession ratio (MPR) was ≥80%. Discontinuation rates were calculated based on patients who stopped therapy (60 day window) or who were switched to another DMT. Compliance and discontinuation rates were collected for a 6-month period and discontinuation for 12 and 24-month periods. Cohorts were from 2012 to 2015 (rolling 36 months total) respectively. RESULTS:  Compliance data was collected for 11348 patients (fingolimod, n=1476; DMF, n=2800; teriflunomide, n=1113; natalizumab, n=589; BRACE, n=5370). The percentage of patients deemed compliant after 6 months across Canada was higher for fingolimod (77%), compared to natalizumab (69%), DMF (62%), and BRACE (55%) and comparable to teriflunomide (77%). Patients on fingolimod had the lowest discontinuation rate after 6, 12 and 24-month periods (24%, 21%, 26% respectively) compared to: BRACE (48%, 42%, and 58%); natalizumab (34%, 30%, and 53%) and DMF (27%, 29% and 36%); and similar to teriflunomide at 6 and 12-month periods (24% and 23%), 24-month data was not available. CONCLUSIONS:  The percentage of patients deemed compliant and treated with fingolimod was higher than for other DMTs and on par with teriflunomide while the discontinuation rate was lower compared to other DMTs and on par with teriflunomide over the short-term. Unlike other DMTs, the discontinuation rate with fingolimod did not significantly increase over the 24-month period. These findings may inform MS management strategies which may lead to improved clinical and economic outcomes. Findings based in part on data licensed from IMS Health Canada Inc. All Rights Reserved.